TORONTO,ON – Thornhill Medical (Thornhill), a Canadian based medical device developer announced that it has completed its ‘Series A’ offering being fully subscribed by Yonghua Investment Management Co., Ltd. (“Yonghua Capital”) of Shanghai, PRC. Thornhill Medical will use the funding to support working capital for its market released line of emergency mobile products, expand its global sales and marketing presence and continue clinical research in the fields of non-invasive cardiac and brain stress testing.
“The financial investment focus of the Yonghua Capital compliments Thornhill’s approach to clinical research, product development and global commercialization. We are excited to partner with such a dynamic and well-managed professional team as we continue our mission to deliver unique medical devices, using the lung as a portal, to transform current diagnostic and therapeutic patient care,” says Kipton Lade, President & CEO of Thornhill Medical.
Tina Huang, Managing Director of Yonghua Capital Healthcare Investment is “very pleased to announce the deal with another Canadian medical device company, continuing Yonghua’s international strategy in Canada. Thornhill has dynamic management and a robust R&D team, with the capacity to bring exciting innovation and care to patients globally. Coupled with Yonghua’s financial support and specialized resources in the medical industry in China, we will contribute to Thornhill’s continued success, thus facilitating investors’ belief in Yonghua’s value- investing philosophy.”